Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 8 de 8
Deutsches Arzteblatt International ; 119(1-2):A17-A22, 2022.
Article in German | EMBASE | ID: covidwho-1885133
Deutsches Arzteblatt International ; 119(1-2):A17-A22, 2022.
Article in German | Scopus | ID: covidwho-1870844
Deutsches Arzteblatt International ; 118(39):A1762-A1768, 2021.
Article in German | EMBASE | ID: covidwho-1766783
Deutsches Arzteblatt International ; 118(39):A1762-A1768, 2021.
Article in German | Scopus | ID: covidwho-1481698
J Crohns Colitis ; 16(2): 251-258, 2022 Feb 23.
Article in English | MEDLINE | ID: covidwho-1352156


BACKGROUND: Vaccination is a promising strategy to protect vulnerable groups like immunocompromised inflammatory bowel disease [IBD] patients from an infection with SARS-CoV-2. These patients may have lower immune responses. Little is known about the cellular and humoral immune response after a SARS-CoV-2 vaccination in IBD patients. METHODS: Totals of 28 patients with IBD and 27 age- and sex-matched healthy controls were recruited at Jena University Hospital. Blood samples were taken before, after the first, and in a subgroup of 11 patients after second dose of a SARS-CoV-2 vaccination. Cellular immune response, including IFN-γ and TNF-α response and antibody titres, were analysed. RESULTS: Overall, 71.4% of the IBD patients and 85.2% of the controls showed levels of anti-SARS-CoV-2 antibodies above the cutoff of 33.8 BAU/ml [p = 0.329] after the first dose. Even in the absence of SARS-CoV-2 antibodies, IBD patients showed significant T cell responses after first SARS-CoV-2 vaccination compared with healthy controls, which was not influenced by different immunosuppressive regimens. Associated with the vaccination, we could also detect a slight increase of the TNF production among SARS-CoV-2-reactive TH cells in healthy donorsn [HD] and IBD patients. After the second dose of vaccination, in IBD patients a further increase of humoral immune response in all but one patient was observed. CONCLUSIONS: Already after the first dose of a SARS-CoV-2 vaccination, cellular immune response in IBD patients is comparable to controls, indicating a similar efficacy. However, close monitoring of long-term immunity in these patients should be considered.

COVID-19 , Inflammatory Bowel Diseases , Antibodies, Viral , COVID-19 Vaccines , Humans , Immunocompromised Host , SARS-CoV-2 , Vaccination
J Crohns Colitis ; 14(12): 1702-1708, 2020 Dec 02.
Article in English | MEDLINE | ID: covidwho-1066287


BACKGROUND: The coronavirus disease 2019 [COVID-19] pandemic is affecting lives worldwide. The influence of inflammatory bowel disease [IBD] medication and IBD itself on COVID-19 is controversial. Additionally, IBD-focused guidance is scarce. OBJECTIVE: Our aims were to determine COVID-19 prevalence/exposure, perception and information sources, medication compliance, patient behaviour and physician contact among patients with IBD compared with non-IBD controls. METHODS: A cross-sectional anonymous survey of patients with IBD [N = 415] at one university IBD clinic and one gastroenterology practice, matched 4:1 with control participants [N = 116], was performed. RESULTS: Patients with IBD had a high fear of infection. This was more pronounced in patients taking immunosuppressants and it extended to hospitals, private practices and public places, such as supermarkets. IBD patients reported leaving their homes less frequently than their peers without IBD. A total of 90% of patients with IBD reported washing their hands more frequently. Patients taking immunosuppressants were concerned about interactions between medication and COVID-19, whereas patients taking 5-aminosalicylates were not. Nonetheless, 96.4% of patients adhered to continuing their medication. Patients sought guidance primarily from television and internet news sites. Video consultations were found to be a suitable solution for a subset of patients who are young, have a high level of fear and leave their home less frequently than their peers, whereas overall acceptance of video consultations was limited. CONCLUSION: Patients with IBD are significantly more affected by the COVID-19 pandemic than their non-IBD peers, but they continue to adhere to their medication regimens. IBD-focused COVID-19 information should be actively conveyed.

Attitude to Health , COVID-19/psychology , Health Behavior , Inflammatory Bowel Diseases/psychology , Adaptation, Psychological , Adolescent , Adult , Aged , Aged, 80 and over , Anti-Inflammatory Agents/therapeutic use , COVID-19/complications , COVID-19/epidemiology , COVID-19/prevention & control , Case-Control Studies , Cross-Sectional Studies , Fear , Female , Germany/epidemiology , Health Knowledge, Attitudes, Practice , Health Surveys , Humans , Immunosuppressive Agents/therapeutic use , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/drug therapy , Male , Medication Adherence/psychology , Medication Adherence/statistics & numerical data , Middle Aged , Pandemics/prevention & control , Patient Acceptance of Health Care/psychology , Patient Acceptance of Health Care/statistics & numerical data , Physician-Patient Relations , Prevalence , Young Adult